Review
Clinical Neurology
Duncan Smyth, Zelie Britton, Louisa Murdin, Qadeer Arshad, Diego Kaski
Summary: Vestibular migraine is a common but overlooked neurological condition that causes episodic vertigo. The quality of existing treatment evidence is low, and further clinical trials are needed for improvement. This article provides practical treatment recommendations for adults and discusses the direction for future clinical trials.
Review
Clinical Neurology
Xiuyuan Zhao, Xiaolin Xu, Qingyun Li
Summary: In this meta-analysis, galcanezumab showed superior efficacy compared to placebo in reducing monthly migraine days and secondary outcomes. The occurrence of adverse events and anti-drug antibodies did not significantly differ between the galcanezumab and placebo groups. Galcanezumab was concluded to be a safe and effective treatment for adult patients with episodic and chronic migraine.
JOURNAL OF NEUROLOGY
(2021)
Article
Food Science & Technology
Ilenia Corbelli, Angela Verzina, Ilaria Leone De Magistris, Gioacchino De Vanna, Paolo Eusebi, Giorgia Mataluni, Antonio Pisani, Addolorata Maria Pia Prudenzano, Maria Trojano, Marianna Delussi, Marina De Tommaso, Antonio Russo, Marcello Silvestro, Gioacchino Tedeschi, Paolo Calabresi, Paola Sarchielli
Summary: This multicentric prospective real-life study aimed to evaluate the efficacy and safety of long-term use with onabotulinumtoxinA in chronic migraine prophylaxis. The study found that chronic migraine patients treated with onaBT-A had significant improvement and good safety in both the first and second year of treatment.
Review
Pharmacology & Pharmacy
Yao-Yao Chen, Xiao-Qian Ye, Tai-Chun Tang, Tian-Wei She, Min Chen, Hui Zheng
Summary: This study conducted an adjusted indirect comparison between CGRPmAbs and BoNT-A, finding similar effectiveness in the preventive treatment of chronic migraine. BoNT-A may be preferentially selected due to its cost-effectiveness. Further studies with direct comparison are needed to confirm these findings.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Clinical Neurology
Stefan Evers, Achim Frese, Oliver Summ, Ingo W. Husstedt, Martin Marziniak
Summary: The study evaluated the efficacy and tolerability of levetiracetam as a prophylactic treatment for episodic migraine. The results showed that levetiracetam has some potential in the treatment of episodic migraine, but it is not superior to other anticonvulsant drugs. Levetiracetam showed better efficacy in patients with migraine with aura and in less affected migraine patients.
Article
Anesthesiology
Katharina Schmidt, Tobias Berding, Julian Kleine-Borgmann, Harald Engler, Dagny Holle-Lee, Charly Gaul, Ulrike Bingel
Summary: Positive treatment expectation plays an important role in the efficacy of preventive treatment for migraine, especially in chronic migraine patients and those with prior treatment experience.
Article
Clinical Neurology
Yan Tereshko, Simone Dal Bello, Cherubino Di Lorenzo, Sara Pez, Alice Pittino, Roberto Sartor, Francesca Filippi, Christian Lettieri, Enrico Belgrado, Riccardo Garbo, Giovanni Merlino, Gian Luigi Gigli, Mariarosaria Valente
Summary: This retrospective single-center real-life study aimed to evaluate the efficacy of a 2:1 ketogenic diet and a Low-Glycemic-index Diet in chronic and high-frequency episodic migraine patients. The results showed that both diets were effective in reducing migraine symptoms and related disability.
JOURNAL OF HEADACHE AND PAIN
(2023)
Article
Clinical Neurology
Alberto Raggi, Licia Grazzi, Erika Guastafierro, Alessia Marcassoli, Marco Passavanti, Danilo Antonio Montisano, Domenico D'Amico
Summary: This study compares the cost drivers between chronic migraine with medication overuse headache (CM-MOH) and episodic migraine, and evaluates the impact of improving migraine symptoms on disease cost. Significant reductions in headache frequency and its costs were observed, with the majority of cost reduction attributed to decreased indirect costs.
NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Carlo Lovati, Caterina Mariotti d'Alessandro, Stefania Della Ventura, Fulvio Muzio, Leonardo Pantoni
Summary: The study suggests that a ketogenic diet (KD) may be a useful option for refractory migraine, as it can significantly reduce migraine attack frequency and headache intensity. Ketones appear to play a role in migraine modulation.
NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Francesca Schiano di Cola, Marco Bolchini, Giulia Ceccardi, Salvatore Caratozzolo, Paolo Liberini, Renata Rao, Alessandro Padovani
Summary: This study compared the efficacy of anti-CGRP versus anti-CGRP-R monoclonal antibodies in patients with high frequency episodic and chronic migraine. The results showed that the anti-CGRP group had significantly lower migraine days and MIDAS scores compared to the anti-CGRP-R group.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Valerio Spuntarelli, Andrea Negro, Michelangelo Luciani, Enrico Bentivegna, Paolo Martelletti
Summary: Eptinezumab shows promising results in preventing migraines, with significant efficacy in several trials. However, there are still knowledge limitations regarding its use during pregnancy or breastfeeding, as well as its pharmacokinetics and metabolism. These are concerns that need to be addressed in future studies.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2021)
Article
Clinical Neurology
Samira Khani, Seyed Amir Hejazi, Mehdi Yaghoubi, Ehsan Sharifipour
Summary: The study assessed the efficacy of concurrent magnesium-sodium valproate therapy in comparison to magnesium or sodium valproate alone in migraine prophylaxis. Results showed that magnesium enhances the antimigraine properties of sodium valproate and reduces the required valproate dose for migraine prophylaxis.
JOURNAL OF HEADACHE AND PAIN
(2021)
Article
Clinical Neurology
Candice M. Todd, Claire H. Sandoe, Christine Lay
Summary: This article provides an outline of evidence-based pharmacological and nonpharmacological strategies for clinicians to build a toolbox for managing migraine in patients.
SEMINARS IN NEUROLOGY
(2022)
Article
Pharmacology & Pharmacy
Fan Cheng, Fayyaz Ahmed
Summary: This article evaluates the mechanisms of action, efficacy, safety, and adverse events of OnabotulinumtoxinA in the prophylaxis of chronic migraine. Studies indicate that OnabotulinumtoxinA is safe and effective in improving symptoms in patients with chronic migraine.
EXPERT OPINION ON DRUG SAFETY
(2021)
Article
Clinical Neurology
Richard B. Lipton, Stewart J. Tepper, Stephen D. Silberstein, David Kudrow, Messoud Ashina, Uwe Reuter, David W. Dodick, Feng Zhang, Gregory A. Rippon, Sunfa Cheng, Daniel D. Mikol
Summary: During long-term erenumab treatment, over half of patients with chronic migraine reverted to episodic migraine, with most of them experiencing persistent reversion. Some patients may achieve delayed reversion to episodic migraine.
Review
Biochemistry & Molecular Biology
Anna Ferrari, Carlo Baraldi, Emilio Sternieri
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
(2015)
Article
Chemistry, Analytical
Anna Ferrari, Ilaria Tiraferri, Federica Palazzoli, Patrizia Verri, Daniele Vandelli, Filippo Marchesi, Michela Ciccarese, Manuela Licata
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
(2015)
Article
Chemistry, Analytical
Patrizia Verri, Cecilia Rustichelli, Federica Palazzoli, Daniele Vandelli, Filippo Marchesi, Anna Ferrari, Manuela Licata
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
(2015)
Article
Pharmacology & Pharmacy
Anna Ferrari, Manuela Licata, Cecilia Rustichelli, Carlo Baraldi, Daniele Vandelli, Filippo Marchesi, Federica Palazzoli, Patrizia Verri, Enrico Silingardi
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2017)
Article
Pharmacology & Pharmacy
Anna Ferrari, Carlo Baraldi, Manuela Licata, Daniele Vandelli, Filippo Marchesi, Federica Palazzoli, Patrizia Verri, Cecilia Rustichelli, Enrico Giuliani, Enrico Silingardi
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2016)
Article
Biochemical Research Methods
Daniele Vandelli, Federica Palazzoli, Patrizia Verri, Cecilia Rustichelli, Filippo Marchesi, Anna Ferrari, Carlo Baraldi, Enrico Giuliani, Manuela Licata, Enrico Silingardi
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
(2016)
Article
Chemistry, Analytical
Manuela Licata, Cecilia Rustichelli, Federica Palazzoli, Anna Ferrari, Carlo Baraldi, Daniele Vandelli, Patrizia Verri, Filippo Marchesi, Enrico Silingardi
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
(2016)
Review
Pharmacology & Pharmacy
Anna Ferrari, Cecilia Rustichelli, Carlo Baraldi
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2017)
Article
Clinical Neurology
Anna Ferrari, Carlo Baraldi, Manuela Licata, Cecilia Rustichelli
Article
Substance Abuse
Anna Ferrari, Ilaria Tiraferri, Federica Palazzoli, Manuela Licata
EUROPEAN ADDICTION RESEARCH
(2014)
Article
Biochemical Research Methods
Anna Ferrari, Cecilia Rustichelli, Carlo Baraldi, Daniele Vandelli, Patrizia Verri, Filippo Marchesi, Manuela Licata
DRUG TESTING AND ANALYSIS
(2019)
Review
Pharmacology & Pharmacy
Cecilia Rustichelli, Flavia Lo Castro, Carlo Baraldi, Anna Ferrari
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2020)
Article
Clinical Neurology
Cecilia Rustichelli, Elisa Bellei, Stefania Bergamini, Emanuela Monari, Flavia Lo Castro, Carlo Baraldi, Aldo Tomasi, Anna Ferrari
Summary: This study found that serum levels of pregnenolone sulfate and pregnanolone were significantly lower in women with menstrually-related migraine compared to controls, while estradiol levels were similar. In the migraine group, serum levels of pregnenolone sulfate were negatively correlated with migraine history and age, while in the control group, pregnenolone sulfate levels were not age-related. These findings suggest a potential role of neurosteroids in migraine pathophysiology and support the therapeutic potential of restoring low neurosteroid levels in migraine treatment.
JOURNAL OF HEADACHE AND PAIN
(2021)
Article
Medicine, General & Internal
Elisa Bellei, Stefania Bergamini, Cecilia Rustichelli, Emanuela Monari, Michele Dal Porto, Alessandro Fiorini, Aldo Tomasi, Anna Ferrari
Summary: This study compared the urinary proteome of women suffering from different types of migraines with non-headache women, identifying potential biomarkers related to the pathophysiology of migraines. The findings may offer insights into better diagnosis and treatment of migraines.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Pharmacology & Pharmacy
Cecilia Rustichelli, Rossella Avallone, Anna Ferrari
Summary: This article summarizes and evaluates the available data on Atogepant for the prophylaxis of episodic migraine. From pivotal trials, the efficacy and tolerability of Atogepant in episodic migraine prophylaxis seem comparable to those of CGRP monoclonal antibodies, even if comparative studies have not been conducted. To date, limited information is available on Atogepant, including the optimal dose and duration of therapy; hence, it is difficult to establish whether it could be a first-line drug for migraine prophylaxis. Furthermore, it is important to evaluate if Atogepant use is associated with the risk of cardiovascular and cerebrovascular events, which could result from potent and persistent blockade of vasodilation by CGRP.
EXPERT OPINION ON PHARMACOTHERAPY
(2022)